TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Genmab ( (GMAB) ) has shared an update.
On December 1, 2025, Genmab A/S announced transactions involving shares and linked securities conducted by its managerial employees and their closely associated persons. These transactions, which were acquisitions due to the vesting of restricted stock units, reflect internal movements within the company’s stock holdings. The disclosure is in compliance with market regulations and highlights the vested interests of key personnel in Genmab’s operational success.
The most recent analyst rating on (GMAB) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Genmab stock, see the GMAB Stock Forecast page.
Spark’s Take on GMAB Stock
According to Spark, TipRanks’ AI Analyst, GMAB is a Outperform.
Genmab’s strong financial performance and positive earnings call sentiment are the primary drivers of its score. The company’s strategic initiatives and solid valuation further support its potential, despite some technical indicators suggesting caution.
To see Spark’s full report on GMAB stock, click here.
More about Genmab
Genmab A/S is a biotechnology company based in Denmark, primarily focused on developing innovative antibody therapeutics for the treatment of cancer. The company is listed on Nasdaq under the ticker GMAB and operates within the pharmaceutical and healthcare industry.
Average Trading Volume: 2,141,439
Technical Sentiment Signal: Buy
Current Market Cap: $19.51B
Find detailed analytics on GMAB stock on TipRanks’ Stock Analysis page.